Niveau de preuve du suivi thérapeutique pharmacologique du 5-fluorouracile au décours de son administration dans le traitement des cancers des voies aérodigestives supérieures et du cancer colorectal

Thyss, 1986, Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer, Cancer Chemother Pharmacol, 16, 64, 10.1007/BF00255288 Santini, 1989, 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer, Br J Cancer, 59, 287, 10.1038/bjc.1989.59 Vokes, 1996, Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer, J Clin Oncol, 14, 1663, 10.1200/JCO.1996.14.5.1663 Milano, 1994, Relationship between fluorouracil systemic exposure and tumor response and patient survival, J Clin Oncol, 12, 1291, 10.1200/JCO.1994.12.6.1291 Fety, 1994, Clinical randomized study of 5FU monitoring versus standard dose in patients with head and neck cancer: preliminary results, Anticancer Res, 14, 2347 Beneton, 2007, Relationship between 5-fluorouracil exposure and outcome in patients receiving continuous venous infusion with or without concomitant radiotherapy, Br J Clin Pharmacol, 64, 613, 10.1111/j.1365-2125.2007.02951.x Schneider, 1995, Phase II trial of cisplatin, fluorouracil, and pure folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey, J Clin Oncol, 13, 1656, 10.1200/JCO.1995.13.7.1656 de Gramont, 1997, Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly highdose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study, J Clin Oncol, 15, 808, 10.1200/JCO.1997.15.2.808 Legand, 2009, 5-fluorouracil (5-FU) plasma exposure and outcome in patients receiving a TPF (taxotere, cisplatin, 5-FU) chemotherapy, Fundam Clin Pharmacol, 23, 25 Gamelin, 1996, Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU, Cancer, 77, 441, 10.1002/(SICI)1097-0142(19960201)77:3<441::AID-CNCR4>3.0.CO;2-N Ardalan, 1991, A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma, J Clin Oncol, 9, 625, 10.1200/JCO.1991.9.4.625 de Gramont, 2000, Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer, J Clin Oncol, 18, 2938, 10.1200/JCO.2000.18.16.2938 Trump, 1991, Pharmacokinetic and pharmacodynamics analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole, J Clin Oncol, 9, 2027, 10.1200/JCO.1991.9.11.2027 Milano, 1988, Dose versus pharmacokinetics for predicting tolerance to 5-day continuous infusion of 5-FU, Int J Cancer, 41, 537, 10.1002/ijc.2910410411 Yoshida, 1990, Clinical significance of monitoring serum levels of 5-fluorouracil by continuous infusion in patients with advanced colonic cancer, Cancer Chemother Pharmacol, 26, 352, 10.1007/BF02897292 van Groeningen, 1988, Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule, Cancer Res, 48, 6956 Ychou, 1998, A prospective randomized study comparing high- and low-dose leucovorin combined with same-dose 5-fluorouracil in advanced colorectal cancer, Am J Clin Oncol, 21, 233, 10.1097/00000421-199806000-00004 Gamelin, 1998, Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients, J Clin Oncol, 16, 1470, 10.1200/JCO.1998.16.4.1470 Ychou, 2003, Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen, Cancer Chemother Pharmacol, 52, 282, 10.1007/s00280-003-0658-0 Gamelin, 2008, Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer, J Clin Oncol, 26, 2099, 10.1200/JCO.2007.13.3934 Capitain, 2008, The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer, Pharmacogenomics J, 8, 256, 10.1038/sj.tpj.6500476 Rouits, 2004, Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients, Clin Cancer Res, 10, 5151, 10.1158/1078-0432.CCR-03-0548 Boisdron-Celle, 2007, 5-fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency, Cancer Lett, 249, 271, 10.1016/j.canlet.2006.09.006 Murphy, 1987, Stability of 5-fluorouracil in whole blood and plasma, Clin Chem, 33, 2299, 10.1093/clinchem/33.12.2299 Beumer, 2009, Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer, Ther Drug Monit, 31, 688, 10.1097/FTD.0b013e3181b9b8c0 Pinedo, 1988, Fluorouracil: biochemistry and pharmacology, J Clin Oncol, 6, 1653, 10.1200/JCO.1988.6.10.1653 Fleming, 1992, No effect of dose, hepatic function, or nutritional status on 5-FU clearance following continuous (5-day), 5-FU infusion, Br J Cancer, 66, 668, 10.1038/bjc.1992.335 Lu, 1993, Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy, Cancer Res, 53, 5433 van Kuilenburg, 2004, Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil, Eur J Cancer, 40, 939, 10.1016/j.ejca.2003.12.004 Morel, 2006, Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance, Mol Cancer Ther, 5, 2895, 10.1158/1535-7163.MCT-06-0327 Tuchman, 1985, Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity, N Engl J Med, 313, 245, 10.1056/NEJM198507253130407 Etienne, 1998, Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis, Eur J Cancer, 34, 92, 10.1016/S0959-8049(97)00345-6 Ho, 2000, Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer, Cancer Chemother Pharmacol, 46, 351, 10.1007/s002800000156 Harris, 1990, Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion, Cancer Res, 50, 197 Takimoto, 1996, Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency, Clin Cancer Res, 2, 477 Le Guellec, 2009, Méthodologie pour l’évaluation du niveau de preuve du suivi thérapeutique pharmacologique, La Lettre du Pharmacologue, 23, 21